# OnCo record polycythaemia-vera (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/polycythaemia-vera/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "polycythaemia-vera" ;
  schema:name "Polycythaemia vera (PV)"@en ;
  schema:alternateName "Polycythemia vera"@en, "PV"@en, "Primary polycythaemia"@en, "Vaquez disease"@en, "Vaquez-Osler disease"@en ;
  schema:description "Polycythaemia vera is a slow blood cancer in which a single faulty gene, JAK2, makes the bone marrow produce too many red cells. Thick blood causes clots, so treatment thins it (blood removal, aspirin) and, for higher-risk patients, calms the marrow with hydroxyurea, interferon or ruxolitinib; a hepcidin mimic, rusfertide, now controls red cell counts without regular blood removal."@en ;
  schema:url <https://onco.cc/cancers/polycythaemia-vera/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Polycythemia_vera> ;
  schema:citation <https://en.wikipedia.org/wiki/Polycythemia_vera>, <https://www.mpnresearchfoundation.org/polycythemia-vera/>, <https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq> ;
  onco:tag "polycythaemia-vera", "mpn" ;
  onco:related <https://onco.cc/cancers/essential-thrombocythaemia/>, <https://onco.cc/cancers/primary-myelofibrosis/> ;
  onco:terms <https://onco.cc/terms/mpn-driver-mutations/> ;
  onco:pipeline <https://onco.cc/drugs/givinostat/>, <https://onco.cc/drugs/bomedemstat/>, <https://onco.cc/trials/nct06093672/>, <https://onco.cc/ideas/idea-pv-clone-directed-therapy/>, <https://onco.cc/ideas/idea-pv-hepcidin-first/> ;
  onco:standardOfCare <https://onco.cc/targets/jak2/>, <https://onco.cc/terms/erythrocytosis/>, <https://onco.cc/drugs/aspirin/>, <https://onco.cc/trials/cyto-pv/>, <https://onco.cc/terms/phlebotomy/>, <https://onco.cc/terms/haematocrit/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/trials/low-pv/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/trials/proud-pv/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/trials/response/>, <https://onco.cc/trials/response-2/>, <https://onco.cc/trials/majic-pv/>, <https://onco.cc/drugs/rusfertide/>, <https://onco.cc/trials/verify/>, <https://onco.cc/terms/hepcidin/>, <https://onco.cc/terms/aquagenic-pruritus/>, <https://onco.cc/terms/erythromelalgia/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/terms/post-pv-myelofibrosis/> .